AZTREONAM 1gm. IP

An antimicrobial agent with selective activity against gram-negative bacteria. (D H Johnson, 1995) A valuable addition to the available antibiotics for the treatment of gram-negative infections. (A R Tunkel, 1990) Provides excellent coverage against a broad range of aerobic gram-negative bacteria. (D M Ennis, 1995) A safe alternative antibiotic for managing gram-negative infections in penicillin-allergic patients. (Saxon, 1989) An effective treatment against resistant strains of gram-negative organisms, which are often involved in nosocomial infections. (D H Johnson, Aztreonam, 1995) A safe, effective alternative to aminoglycoside therapy. (Cook, 1988) A valuable agent with an excellent safety profile for the treatment of pneumonia. An effective, safe therapy for serious and life-threatening infections caused by multiresistant aerobic gram negative bacteria. (Neu, 1988) Superior to tobramycin for the treatment of pneumonia due to susceptible gram-negative bacteria in critical care patients. (J J Schentag, 1985) Offers an advantage over aminoglycosides as it is neither ototoxic nor nephrotoxic. (Roberts, 1988) More effective than amikacin in treating respiratory tract infections. (E Rabinad, 1989)